ReviewCurrent topics in medicinal chemistry2017
Metabolomics Applications in Precision Medicine: An Oncological Perspective.
Review in Current topics in medicinal chemistry, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 1 synthesis or guideline pooled it, 95 citations in OpenAlex.
- Emerging biomarkers for non-invasive diagnosis and treatment of cancer: a systematic review.Frontiers in oncology · 2024Pooled it
- Determination of Untargeted Metabolomic Profile in Breath Condensate Using LC-QTOF/MS and Investigation of Potential Lung Cancer-Specific Biomarkers.Thoracic research and practice · 2025Article
- Decoding the mechanisms behind second primary cancers.Journal of translational medicine · 2025Review
- Metabolomics in cancer detection: A review of techniques, biomarkers, and clinical utility.BioMedicine · 2025Review
- Personalized Medicine Approach to Proteomics and Metabolomics of Cytochrome P450 Enzymes: A Narrative Review.European journal of drug metabolism and pharmacokinetics · 2024Review
- A non-invasive method for concurrent detection of multiple early-stage cancers in women.Scientific reports · 2023Article
- Prospective Metabolomic Studies in Precision Medicine: The AKRIBEA Project.Handbook of experimental pharmacology · 2023Article
- Microbiome and metabolic features of tissues and feces reveal diagnostic biomarkers for colorectal cancer.Frontiers in microbiology · 2023Article
- Article
- Exploring Metabolic Signatures of Ex Vivo Tumor Tissue Cultures for Prediction of Chemosensitivity in Ovarian Cancer.Cancers · 2022Article
- Predicting dynamic response to neoadjuvant chemotherapy in breast cancer: a novel metabolomics approach.Molecular oncology · 2022Article
- A Comprehensive Metabolomics Analysis of Fecal Samples from Advanced Adenoma and Colorectal Cancer Patients.Metabolites · 2022Article
- Precision medicine journey through omics approach.Journal of diabetes and metabolic disorders · 2022Review
- Prediction of Metabolic Profiles from Transcriptomics Data in Human Cancer Cell Lines.International journal of molecular sciences · 2022Article
- Article
- Revealing the Mysteries of Acute Myeloid Leukemia: From Quantitative PCR through Next-Generation Sequencing and Systemic Metabolomic Profiling.Journal of clinical medicine · 2022Review
- Cerebrospinal Fluid Sphingomyelins in Alzheimer's Disease, Neurodegeneration, and Neuroinflammation.Journal of Alzheimer's disease : JAD · 2022Article
- Unraveling Autocrine Signaling Pathways through Metabolic Fingerprinting in Serous Ovarian Cancer Cells.Biomedicines · 2021Article
- Metabolomics in Autoimmune Diseases: Focus on Rheumatoid Arthritis, Systemic Lupus Erythematous, and Multiple Sclerosis.Metabolites · 2021Review
- Integrated genomic-metabolic classification of acute myeloid leukemia defines a subgroup with NPM1 and cohesin/DNA damage mutations.Leukemia · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nowadays, cancer therapy remains limited by the conventional one-size-fits-all approach. In this context, treatment decisions are based on the clinical stage of disease but fail to ascertain the individual ´s underlying biology and its role in driving malignancy. The identification of better therapies for cancer treatment is thus limited by the lack of sufficient data regarding the characterization of specific biochemical signatures associated with each particular cancer patient or group of patients. Metabolomics approaches promise a better understanding of cancer, a disease characterized by significant alterations in bioenergetic metabolism, by identifying changes in the pattern of metabolite expression in addition to changes in the concentration of individual metabolites as well as alterations in biochemical pathways. These approaches hold the potential of identifying novel biomarkers with different clinical applications, including the development of more specific diagnostic methods based on the characterization of metabolic subtypes, the monitoring of currently used cancer therapeutics to evaluate the response and the prognostic outcome with a given therapy, and the evaluation of the mechanisms involved in disease relapse and drug resistance. This review discusses metabolomics applications in different oncological processes underlining the potential of this omics approach to further advance the implementation of precision medicine in the oncology area.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.